An update on the shortage of radium-223 (Xofigo)

On October 21, here in the USA, Bayer HealthCare Pharmaceuticals issued a Dear Healthcare Professional letter to medical professionals indicating that the company still does not know when it is likely to be able to start to re-supply this radiopharmaceutical agent for the treatment of late-stage prostate cancer. … READ MORE …

GDF-15, vitamin D, and risk for prostate cancer

A new study by Lambert et al. in the journal Prostate proposes that some forms of chronic prostatic inflammation, driven by low levels of a molecule known as growth differentiation factor-15 (GDF-15), may lead to prostate cancer development. … READ MORE …

Two different “takes” from the results of the CHAARTED trial

In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …

Resistance training and quality of life among men on ADT

A newly published study has added to the mounting evidence that resistance training and related exercises are a valuable complement to medical care for men on androgen deprivation therapy (ADT). … READ MORE …

Introduction of a proposed National Prostate Cancer Council Act

So, according to a communication to its members from the American Urological Association (AUA), U.S. Senators Barbara Boxer (D, CA) and Jeff Sessions (R, AL) have just introduced S. 2813, the National Prostate Cancer Council Act. … READ MORE …

Prospective data on the use of MRI-guided vs. TRUS-guided biopsy

Two newly published papers in the November issue of the Journal of Urology address prospective studies of the use of differing forms of MRI-guided biopsy in the diagnosis of prostate cancer. … READ MORE …

Disulfiram in prostate cancer revisited (this time with copper supplementation)

Not so long ago (back in late 2013), Schweizer et al. reported data from a very small trial of an old drug called disulfiram (also known as Antabuse) in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,153 other followers